凱萊英(06821.HK)獲上海市政府轉讓約96.5畝土地建生物藥研發及商業化生產基地
凱萊英(06821.HK)公佈,已於上星期五(4日)與上海市政府轄下上海市工業綜合開發區有限公司簽署投資協議,內容關於向集團轉讓位於上海市工業綜合開發區內總面積約96.5畝土地,及由集團投資建設生物藥CDMO研發及商業化生產基地。
投資項目將採用全球領先的製藥工藝技術,覆蓋包括新型抗體藥物、抗體偶聯藥物(ADC)在內的生物藥的研發與生產。投資項目預計總投資額約30億元人民幣,預計資金來源包括自有資金或自籌資金。
有關受讓土地的詳細條款和條件,將在另行簽訂的土地出讓合同中約定,集團尚未就項目實施取得任何具法律效力的資質或證書,項目實施需完成相關主管部門的審批手續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.